The cost-benefit ratio of tetravalent rhesus rotavirus vaccine (RRV-TV) in Finland for prevention of rotavirus gastroenteritis was assessed in a randomized, double-blind, placebo-controlled trial. Costs related to vaccination, side effects, and gastroenteritis were identified. Children received RRV-TV (n Å 1,191) or placebo (n Å 1,207) at 2, 3, and 5 months of age with other infant vaccinations. Prospective follow-up averaged 1.0 years per child. An intention-to-treat analysis was performed from the perspective of society. Nine cases of severe rotavirus gastroenteritis occurred in the RRV-TV group, versus 100 in the placebo group (P õ .0001); mean cost per vaccinated child was 4 Finnish marks (FIM) in the RRV-TV group, versus 203 FIM in the placebo group. Side effects with related costs occurred after 11% and 7% of doses in the RRV-TV group and placebo group, respectively (P õ .001); mean cost per child was 89 FIM vs. 75 FIM. The break-even cost (i.e., net benefit, excluding cost of vaccine) of RRV-TV in prevention of severe rotavirus gastroenteritis was 109 FIM (U.S. $19.60) per child.
Rotavirus is a major cause of severe acute gastroenteritis include direct medical costs as well as indirect costs, such as for parents' lost work hours. With regard to childhood rotavirus (GE) in young children worldwide. Rotavirus infects nearly all children by the age of 5 years [1] . The incidence rate in devel-GE (R-GE) in industrialized countries, where two-parent participation in the workforce and single-parent families are increasoping countries is not much different from that in industrialized countries, but the mortality rate is considerably higher: 500,000 ing, this may be a major cost factor. Thus far, only a few reports on the cost-effectiveness of to 800,000 deaths per year in the developing world are attributable to rotavirus [2, 3] . However, while rotavirus may not be rotavirus vaccines in the prevention of GE have been reported [12 -16] , and to our knowledge only one study addressed this a significant cause of death in industrialized countries (20 -40 deaths per year in the United States in recent years [4] ), it issue as a part of a prospective controlled vaccine trial [13] . We conducted a cost-benefit analysis in connection with a is a significant cause of morbidity. It accounts for Ç55,000 hospitalizations annually in the United States and approxidouble-blind, placebo-controlled, randomized trial evaluating the safety and efficacy of the tetravalent rhesus rotavirus vacmately one-third of all hospitalizations due to GE in children [5] . In Finland, approximately two-thirds of hospital admiscine (RRV-TV) among 2,398 Finnish infants. sions for GE among children under 3 years of age were found to be due to rotavirus [6] .
Materials and Methods The ability to prevent this health burden with safe and effective vaccines would be a major public health breakthrough, the Vaccinations of children in Finland, in accordance with the ultimate goal being the incorporation of the vaccine into routine national vaccination program and primary health care protochildhood vaccination schedules worldwide [7] . Progress with cols, are publicly funded and free of charge. Vaccinations are live oral heterologous reassortant vaccines may soon lead to performed by public health nurses at well-baby clinics (Ç1,000 licensure of the first rotavirus vaccines [8 -10] .
in all of Finland). All childhood vaccines are centrally distribFor these reasons, evaluation of the vaccines' cost-benefit uted to well-baby clinics through the National Public Health ratio is of major importance [7, 11] . This evaluation should
Institute. The present study was conducted in the Pirkanmaa district, located in central Finland, which has a population of 435,000 and 100 well-baby clinics. Primary medical care is possible vaccination side effects (SEs), and GE occurring durnormal. GE was defined as diarrhea and/or at least one episode of vomiting within a 24-hour period. The severity of GE was ing the follow-up. Direct costs included the medical costs for vaccination, hospitalization, physician visits, and medication determined by the scoring of clinical signs and symptoms on a 20-point scale. A score of 11 or higher was considered severe as well as nonmedical costs, e.g., travel and additional child care. Indirect costs included lost productivity (i.e., work hours [19] . Children were enrolled in the study consecutively between lost).
24 September 1993 and 30 September 1994. Possible SEs were followed from the day of each vaccination through the follow-
Study Design and Procedures
ing 4 days (postvaccination period). The peridosing period was Children born during the period of July 1993 through July the time between the postvaccination period and the next vacci-1994 in the study area (n Å 5,884) were eligible for participanation. The primary efficacy period started on day 14 after tion in the study. Children were excluded (1) if they had an dose three and ended at the common study end on 30 June underlying disease or condition; (2) if an immunosuppressed 1995. For incompletely vaccinated children the efficacy period individual lived in the household; (3) if they were involved in started 14 days after dose one or dose two. Thus, study children any other investigational clinical trial; or (4) if the family did were followed for either one rotavirus season (1994 -1995) or not have a telephone. Written informed consent was obtained two (1993 -1994 and 1994 -1995) (figure 1). from parents of children during the 1-month visit to their local
The break-even cost for RRV-TV was defined as the net well-baby clinic. The study protocol and consent form combenefit of the program, excluding the cost of all doses of plied with the guidelines of the Food and Drug Administration RRV-TV. of the U.S. Public Health Service and were approved by the Finnish National Agency for Medicines and by the ethical com-
Data Collection
mittees of the Finnish National Public Health Institute, the Tampere University Hospital, the Department of Social and
Vaccination. Data on vaccination costs were collected with Health Care of Tampere City, and the regional investigational use of structured questionnaires filled out by study nurses review boards in the Pirkanmaa area.
(n Å 8) observing a total of 961 vaccination procedures in Children were consecutively enrolled and randomly assigned three different phases of the study (start of the study, middle to receive a study vaccine, either RRV-TV (lyophilized of the study, and established function). In addition, they noted RRV-TV: 4 during the postvaccination period were collected by the parents ture medium) at Ç2 months (50 -130 days), Ç3 months (80 -on postvaccination study cards. These included data on fever, 160 days), and Ç5 months (110 -202 days) of age. There were vomiting, diarrhea, abdominal cramping, decreased appetite, a minimum period of 21 days and a maximum period of 3 excessive crying, coughing, wheezing, runny nose, and level months between two doses. The lyophilized vaccine or placebo of activity and irritability. The exact nature of these SEs will (identical in appearance) was resuspended at room temperature be reported elsewhere. in 3.0 mL of sodium bicarbonate/citric acid (25.6 mg/mL and Study nurses contacted the parents by telephone on days 9.6 mg/mL, respectively) buffer diluent. Infants were given 3 and 6 after each vaccination. For the purpose of this study, 2.5 mL of the resuspended vaccine orally by means of a small parents were asked whether any symptoms as listed on the syringe without a needle. study cards had occurred within the postvaccination period All study vaccinations were planned within the routine childand whether they had caused any excess work for the parents. hood visit schedule at the well-baby clinics and were done If so, the duration of symptoms and cost-items related to together with the infant vaccinations routine in Finland, i.e., these events were noted on structured questionnaires (see with diphtheria-tetanus-pertussis (DTP) vaccinations at 3 and Appendix). Data on children who were hospitalized or at-5 months of age ( figure 1 ). An intention-to-treat analysis was tended the hospital outpatient department were collected done of all infants enrolled who received at least one dose of from patient records by the study doctor (J.J.) and noted on study vaccine. Sensitivity analyses were performed of data a structured questionnaire. from children who received all three doses of study vaccine.
Gastroenteritis. Data on episodes of GE occurring at any time other than the postvaccination period were written down
Definitions and Follow-Up Periods
by the parents on GE study cards. In addition, parents were requested to telephone their respective study nurse whenever Diarrhea was defined as the passage of §3 stools in a 24-hour period that were judged by the parents to be looser than the study child had symptoms of GE. During such an episode, / 9c52$$au07 07-09-98 18:39:36 cidas UC: CID the study nurse called the family daily and collected two cost per child in the RRV-TV group minus the mean total cost per child in the placebo group. The primary outcome stool samples on two different days for detection of rotavirus antigen by an ELISA, performed at the University of Tampwas severe rotavirus GE (SR-GE). In addition, an analysis was performed for all R-GE and for all GE, irrespective of ere [20] . The study nurses also gave advice on management of the episodes.
etiology. We performed sensitivity analyses to assess possible changes If necessary, parents of the patients contacted public health centers, private physicians, or hospital clinics, as they would in the break-even cost with regard to the following most critical variables using data for children who received all three doses have done without participation in the study, for further advice. In addition, study nurses evaluated the occurrence of GE by of study vaccine and had SR-GE as the outcome.
(1) Incidence of R-GE. On the basis of data from the presmaking bimonthly telephone calls to all parents. Finally, all personal notebooks and telephone contact forms of study nurses ent and previous studies [5, 6] , we estimated a low and high cumulative incidence of R-GE among children up to 18 months were reviewed for notes about GE or similar symptoms, and these were compared with the child's medical records after of age (the average age up to which children in the present study were followed). termination of the study to evaluate missed cases of GE in the prospective follow-up. Clinical and cost data related to episodes (2) Cost of inpatient hospitalization, outpatient visits, and primary medical care. First, the lower or upper bound of the of GE were collected with use of structured questionnaires during all interviews in the prospective follow-up, as described interquartal range of the observed costs was used. Second, the 95% confidence interval was calculated for the number of cases above for SEs.
with costs in the RRV-TV and placebo groups and for the three cost types. The estimates for the lower and upper limits of total Analysis costs were calculated with use of these 95% confidence limits, multiplied by the joint average costs in the RRV-TV and plaAll costs (in Finnish marks [FIM], followed by United States dollars [$U.S.] in parentheses) were estimated at the 1993 level cebo groups. (3) Production loss. The analysis was performed with and (1 FIM Å $0.18). Market prices were used whenever available. For public sector services, actual costs were calculated on the without the effect of production loss. The effect of production loss was also estimated for a situation in which a parent/caregiver basis of the normally utilized internal costing practices at the relevant institutions (see Appendix). The following costs were would need to stay home from work to be able to take care of the child for the duration of symptoms (of GE and SEs). It was evaluated: costs for administering RRV-TV at well-baby clinics (with use of two alternative models), hospital inpatient and assumed that these symptoms would prevent the child from being taken care of outside the home (e.g., at a day-care center). outpatient costs, costs of primary medical care (including laboratory and intervention costs), and costs of medication, travel, (4) Cost of vaccination. First, the cost according to model I was varied between the upper and lower bound of the interand production loss.
Initially all costs and consequences were calculated sepaquartal range. (Model I valuated the extra time needed for study vaccine administration at routine vaccinations, additional rately for the vaccine and placebo groups and for the different follow-up periods. The mean total cost per child convisits needed, and material costs; see Appendix.) Second, the cost according to model II was used. (Model II assumed zero sisted of the sum of the mean costs of vaccinations (excluding the cost of vaccine), treatment of SEs, treatment cost for the extra time needed for study vaccine administration at routine visits.) of GE during the peridosing periods, and treatment of GE during the primary efficacy period. In the placebo group, Fisher's exact test for contingency tables was used for comparisons of proportions. The Kruskal-Wallis test was used for costs due to vaccinations were excluded. The break-even cost for RRV-TV per child was calculated as the mean total comparison of means.
/ 9c52$$au07 07-09-98 18:39:36 cidas UC: CID Results extra time needed for administration of the study vaccine was 4 minutes. The cost of extra material needed and of handling Altogether, 2,398 children were enrolled in the study (41% for one dose of vaccine was 1.02 FIM ($0.18). The average of all children born in the study area during the enrollment cost for administering one dose of study vaccine, excluding period), of whom 1,191 received the RRV-TV and 1,207 the the cost of the vaccine, was either 26 FIM ($4.70) (model I) placebo. In both groups 95% of children received the full threeor 3.3 FIM ($0.60) (model II) (see Appendix). dose regimen of vaccine, and almost all completed the follow-
The cost for adding the rotavirus vaccine to the routine up (figure 2). The average follow-up time was 1.0 years. The vaccination program (training of health care professionals and follow-up time for GE after complete vaccination was two full the public; updating and printing the vaccinators' guide) was rotavirus seasons for only 177 children. The majority of the 100,000 FIM ($18,000) during the first year and zero thereafter; children were either vaccinated and followed (as partly vaccisince this cost was negligible, it was not included in the present nated) for GE during the first rotavirus season and followed analysis. (as fully vaccinated) during the second season (n Å 1,486) or vaccinated after the first season and followed only during the second season (n Å 619).
Side Effects
For the total of 7,013 doses of study vaccine given for all Vaccination study infants, parents reported 2,845 SEs. Of these SEs, 720 caused excess work for the parents and 642 of them caused The study plan incorporated the study vaccine into the Finncosts (390 occurred in those receiving RRV-TV and 252 in ish routine infant vaccination schedule; thus, additional visits those receiving placebo). SEs were significantly more often for administration of the study vaccine only were very infrereported after doses of RRV-TV than of placebo (44% vs. 37%; quent (1% of all visits). During the routine visits the average P õ .001) and so were SEs that created costs (11% vs. 7%; P õ .001). The average number of SEs reported per child was 1.3 in the RRV-TV group, vs. 1.1 in the placebo group (P õ .001), and that of SEs creating costs was 0.3, vs. 0.2 (P õ .001) (table 1). The first vaccination at 2 months of age was the only time when the study vaccine was scheduled to be administered alone (figure 1) and thus was an opportunity for direct comparison of SEs between the two groups. Among completely vaccinated children, the first dose of RRV-TV caused significantly more SEs than did the first dose of placebo (54% vs. 35%; P õ .001), and SEs creating costs were also more common among RRV-TV recipients (11% vs. 3%; P õ .001). Numbers of SEs were comparable in the RRV-TV group and the placebo group for the second and third dose of vaccine. The first dose of RRV-TV caused SEs significantly more often than did the second and third doses of RRV-TV combined (54% vs. 38%; P õ .001). The SEs creating costs were comparable, however (11%, 10%, and 11%, respectively, after the first, second, and third doses of RRV-TV). In-hospital treatment of SEs was infrequent in both groups (table 1) .
Among incompletely vaccinated children, the proportion of infants experiencing SEs as well as SEs creating costs was higher than among completely vaccinated children after their first and second doses combined. This was the case in both vaccine groups. In the RRV-TV group, SEs occurred after 76% of the doses among incompletely vaccinated children, vs. 47% of the doses among completely vaccinated children (P õ .001). In the placebo group the corresponding percentages were 65% and 37% (P õ .001), and for SEs causing costs the respective percentages were 29% vs. 11% (P õ .001) in the RRV-TV group and 16% vs. 6% (P õ .01) in the placebo group.
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Gastroenteritis
In the RRV-TV group, a higher proportion of incompletely vaccinated than completely vaccinated children was hospital-A total of 1,484 episodes of GE (all types) were recorded in ized (2 per 85 doses vs. 2 per 2,264 doses; P õ .01). In addition, the study during the primary efficacy period and the peridosing in both vaccine groups, the duration of SEs among incompletely periods: 689 in the RRV-TV group and 795 in the placebo vaccinated children was longer than among those completing group. Of these, rotavirus was the causative agent in 247 cases the full three-dose regimen (ú4 days vs. 2 -3 days). All these (R-GE; 59 in the RRV-TV group and 188 in the placebo group); circumstances may have influenced the incomplete vaccination 109 were graded SR-GE cases, of which 9 were observed in of these infants (i.e., because of withdrawal of these infants the RRV-TV group and 100 in the placebo group (P õ .001) from the study), but they underline the need to include the (table 2) . Two children in the placebo group had two separate costs of all SEs in the cost-benefit analysis (table 1) .
nonsevere episodes of R-GE. The retrospective analysis for The mean total cost for all SEs per child was 89 FIM ($16.00) missed cases revealed 84 cases of missed GE (4% of all cases in the RRV-TV group vs. 75 FIM ($13.50) in the placebo of GE). They were evenly distributed between the RRV-TV group, and the mean total cost per one vaccine dose was 30 group (40 cases) and placebo group (44 cases). FIM ($5.40) vs. 26 FIM ($4.70), respectively. Inpatient costs Among the children with SR-GE, none of the 9 in the contributed the most to the differences in costs, followed by RRV-TV group vs. 19 of the 100 in the placebo group were costs due to production loss and use of primary medical care hospitalized (P Å .3); for all R-GE, the figures were none of ( NOTE. RRV-TV Å tetravalent rhesus rotavirus vaccine; 1 FIM Å $0.18 U.S. Of the total of 1,484 cases of GE that occurred during the study, cost data were missing on 36 cases (19 cases in the RRV-TV group and 17 in the placebo group). For the different etiology groups, data were missing as follows: SR-GE, none; R-GE, 1 case in the placebo group; GE, 19 cases in the RRV-TV group and 16 in the placebo group. None of the patients whose cost data were missing were hospitalized. The costs described in the table are based on the data from the observed 1,448 cases.
* PDP Å peridosing period. † For calculations of mean cost per child, the missing cost data (n Å 36) were estimated on the basis of information from the 1,448 cases, with matching for the vaccination group and GE severity score. department for treatment of SR-GE occurred in the RRV-TV addition, the shorter duration of symptoms among RRV-TV recipients (mean of 4.8, median of 4, and range of 2 -10 days) group, compared with 28 such visits in the placebo group. In addition, costs due to visits to primary medical care facilities than among placebo recipients (mean of 6.5, median of 6, and range of 3 -26 days) indicates the milder course of GE among and production loss contributed the most to the differences in costs between the two vaccination groups (table 2) .
the RRV-TV recipients. For cases of R-GE and GE (all types), the results were similar The mean cost of SR-GE per vaccinated child was 4 FIM ($0.70) in the RRV-TV group vs. 203 FIM ($36.50) in the to those for SR-GE (table 2 ). An outside caregiver was needed infrequently for the treatment of GE (eight times in the placebo group (table 2). The costs for those SR-GE cases that incurred costs were lower in the RRV-TV group (mean of 499, RRV-TV group and 11 times in the placebo group), and the costs related to this as reported by the parents were negligible. The break-even cost of the vaccine was calculated for all enrolled children (intention-to-treat group), with SR-GE as the of SR-GE among children receiving RRV-TV were milder and less costly to treat than those among placebo recipients. In primary outcome (table 3) . NOTE. Intention-to-treat analysis includes all children initially enrolled who received at least one dose of study vaccine. FIM Å Finnish marks (1 FIM Å $0.18 U.S.); R-GE Å rotavirus GE; RRV-TV Å tetravalent rhesus rotavirus vaccine; SR-GE Å severe rotavirus GE.
* Model I cost of vaccination, i.e., 26 FIM ($4.70) for administering one dose of vaccine. Does not include the cost of RRV-TV.
sponding calculations for R-GE and GE (all types) as secondary 18 months of age varied between 0.10 cases/child and 0.20 cases/child, with 50% of cases being SR-GE, which is in accoroutcomes. The break-even cost of the RRV-TV vaccine among all study children was 109 FIM ($19.60) per child for SR-GE dance with the results of the present study and with those reported previously from Finland and other industrialized counand 122 FIM ($21.90) and 99 FIM ($17.80), respectively, for R-GE and GE (all types). The estimate was similar when only tries [5, 6] . The break-even cost of the vaccine was very sensitive to this variation but remained positive, between 31 FIM fully vaccinated children were included in the analysis (table 3).
($5.60) and 142 FIM ($25.60).
Cost of inpatient hospitalization, hospital outpatient visits,
The single most important variable in the present analysis was inpatient hospitalization. However, because of the small and primary medical care. We estimated the sensitivity of the break-even cost to these variables in two different scenarios. number of inpatient hospitalizations, as well as the large variation in costs related to such cases, the result was very sensitive First, we assumed that SEs would incur more costs in the RRV-TV group (assuming either that inpatient hospitalization to this variable. We performed sensitivity analyses of the breakeven cost with use of data for fully vaccinated children and and outpatient treatment per SE would be more expensive in the RRV-TV group or that there would be more SEs with with SR-GE as the outcome in regard to the most critical variables. Production loss was not included in the analyses.
inpatient hospitalization and outpatient visits in the RRV-TV group). These two approaches were taken for the RRV-TV The model I cost of vaccination was used.
Incidence of rotavirus gastroenteritis. The cumulative incigroup, while the observed values were used for the placebo group. In this scenario, the break-even cost decreased to 30 FIM dence of R-GE among placebo recipients up to 18 months of age in this study was 0.15 cases/child. The proportion of R-GE ($5.40) and 12 FIM ($2.20), respectively, in the two analyses. Second, we assumed that SR-GE would incur more (fewer) cases that were graded as SR-GE was 53%. In the sensitivity analysis, the cumulative incidence of R-GE in children up to costs in the placebo group. This was addressed with the as-/ 9c52$$au07 07-09-98 18:39:36 cidas UC: CID sumption that either the inpatient, outpatient, and primary medOf the initially enrolled 2,398 children, 95% received all three doses of study vaccine and 98% of children completed the followical care treatment of one episode of SR-GE would be more expensive (less expensive) in the placebo group or that there up. Cost data were available for all episodes of SEs, and these data were missing for only 36 episodes (2%) of the total of 1,484 would be more (fewer) episodes of SR-GE treated as inpatient, outpatient, and primary medical care cases in the placebo episodes of GE observed during the follow-up. The retrospective analysis revealed only 4% of GE cases were missed, and these group. The estimate for the break-even cost varied between 10 FIM ($1.80) (observed data for SR-GE in the RRV-TV group were evenly distributed between the study groups. Actual costs, set at the 1993 level, were used for analysis. and a low estimate for SR-GE in the placebo group) and 129 FIM ($23.20) (observed data for SR-GE in the RRV-TV group
The present study showed a distinct benefit from use of the rotavirus vaccine in Finland: the break-even cost (excluding and a high estimate for SR-GE in the placebo group).
Cost of administering RRV-TV. The results in table 3 [14] . The average follow-up time was 1 year. Since the protective inclusion of this variable was 86 FIM ($15.50) (table 3), and it was 82 FIM ($14.80) without it. This reflects the fact that immunity of the RRV-TV probably lasts for longer than just one rotavirus season, the present study likely underestimated Finnish mothers are entitled to a maternity leave for 9 months after delivery, and ú90% of mothers use it and stay home the net benefit attributable to vaccination. Several Finnish studies have shown that the protective efficacy of oral heterologous to take care of the child [21] . In this case, no production loss incurs.
rotavirus vaccines is sustained for two rotavirus seasons [8] .
In the present study, the efficacy against SR-GE was similar We also estimated how the situation would change if parents would have to miss work to take care of a sick child. This was in the first (95%) and second (90%) rotavirus seasons, although efficacy against all R-GE declined from 83% during the first based on the duration of symptoms of SEs and GE reported for those cases that caused excess work for the parents (tables to 63% during the second rotavirus season (reported in detail elsewhere). Moreover, a significant proportion of R-GE in Fin-2 and 3). It was estimated that for this reported total duration of symptoms, the child could not have child care outside the land occurs later, up to 3 years of age [6] . If the efficacy of the RRV-TV remains sustained, the benefits home. If production loss was evaluated this way for both SEs and GE, the break-even cost of the vaccine was 208 FIM of vaccination most likely increase substantially from the level in the present analysis. Among infants in the United States, protec-($37.40); if it was evaluated only for GE, it increased to 296 FIM ($53.30).
tive efficacy of reassortant RRV-TV was relatively similar during the first and second year of follow-up in a study by Bernstein et In the sensitivity analyses all results indicated a positive benefit attributable to the RRV-TV vaccine in preventing al., although the dose of each monovalent component of the vaccine was lower than in the present study [8] . In the present study, SR-GE among completely vaccinated children. The break-even cost of vaccine, based on observed data, was 86 FIM ($15.50) a three-dose regimen was administered. Should the protective efficacy be similar with only one or two doses of vaccine, this per child, and in the sensitivity analyses it varied between 10 FIM ($1.80) and 154 FIM ($27.70) in the Finnish context. would further increase the benefit of vaccinations. During the time of the present study, the epidemiology of R-GE was similar to that reported previously from Finland [6] : in the placebo group the cumulative incidence of R-GE up to Discussion the age of 18 months was 0.15 cases/child, with 53% of episodes graded as severe. Of all hospitalizations due to GE, We collected prospectively detailed cost data on the treatment of episodes of GE and the vaccination procedure as well rotavirus accounted for two-thirds (76%). Of patients with SR-GE, 19% were hospitalized, while the proportion was 9% as treatment of SEs. The aim was to collect data that could most accurately aid decision-makers when considering whether and 3%, respectively, for R-GE and GE as a whole. Fatal cases of R-GE did not occur. The predominant rotavito add rotavirus vaccine into the routine infant vaccination schedule in Finland and Finland. In situations where the incidence of R-GE is higher, the benefits from vaccination affected the RRV-TV and placebo groups equally but could still affect the absolute difference in costs between the most likely increase substantially, as indicated in the sensitivity analysis.
groups. In the present study, travel costs were generally not a major cost factor. Under other circumstances, e.g., when Although the present study population was relatively large, the numbers of observations in the critical variables for the hospital treatment necessitates longer travel, these costs may play a bigger role and most probably add to the benefit of cost-benefit evaluation tended to be small (e.g., the number of hospitalizations), and cost variation was wide. To test the RRV-TV administration.
In the present study, hospitalization due to R-GE was robustness of results, sensitivity analyses were performed with use of detailed data on fully vaccinated children for the most significantly less frequent in the RRV-TV group than in the placebo group. In addition, SR-GE tended to be milder in critical variables.
In the present study, production loss was not a major cost the RRV-TV group: the cost for the treatment of one episode of SR-GE was lower in the RRV-TV group than in the plavariable. Finnish mothers are entitled to a maternity leave covering much of the time when the infant is at highest risk for cebo group, and the duration of symptoms was shorter. This was not detected in the cost-benefit analysis of rotavirus R-GE, and most mothers use this opportunity to stay home [21] . In countries with shorter maternity leaves, the situation vaccine by Griffiths et al., who analyzed this aspect for all cases of R-GE [13] . The effect of inpatient hospital costs may be very different: as estimated in the present study, the break-even cost of the vaccine would increase from 86 FIM varies, depending on the cost structure of health care in each country; Finland represents an average among the OECD ($15.50) up to 296 FIM ($53.30) if parents would need to stay away from work to take care of a child with GE.
countries [26] . The national cost structure needs to be taken into account in application of the present results to other The costs of SEs possibly related to rotavirus vaccines have not been included in previous cost-benefit studies of countries.
On the basis of results of the present study, with assumption the vaccines. We decided to include them since true costs may be incurred because of their treatment. The only occaof a birth cohort of 60,000 infants in Finland annually [27] , a cumulative risk of R-GE of 100% by the age of 5 years [6] , sion when administration of RRV-TV or placebo was scheduled alone was for the first dose of study vaccine, at 2 months and 96% vaccination coverage [28] , immunization could result in savings up to 6.3 million FIM ($1.1 million) each year. The of age. This presented the possibility for evaluation of SEs due to RRV-TV alone. Overall, SEs were reported frequently overall savings, however, would depend on the cost of vaccine. for the first dose of study vaccine, even after the first dose of placebo (for 35% of all doses). This may reflect parents' insecurity in caring for a young infant. NOTE. FIM Å Finnish mark (1 FIM Å $0.18 U.S.); MP Å market price; PC Å personal communication (see Appendix text). Costs were valuated similarly to those above for all rotavirus gastroenteritis and overall gastroenteritis cases.
* Included clinical evaluation prior to vaccination, time used for informing the parents, time used for the complete vaccination, and time used for recording of vaccination; did not include activities related to the trial.
† Established function; includes vaccine quality control, handling, storage, and shipping. ‡ Indicates the mean and range for costs due to respective cost-item. § Data collected on work hours lost for the person accompanying or caring for the child, his/her working status, and annual income.
x Included medication, treatment, diagnostic tests, interventions, salary costs of the hospital staff, and other costs. # Personal communication, P. Alhola, Finnish Association of Private Medical Centers. ** Data collected on mode of travel and two-way distance in kilometers. In addition, data on use of outside caregivers and costs incurred for this were collected.
Laboratory and intervention costs outside hospital. In public on the number of symptomatic days of the child, average daily health centers, laboratory and intervention costs were set according income was used [2] . For all income the obligatory social security to the TAUH tariffs [3] , and in private clinics the tariffs of Yhtypayment by the employer (40% of total income) was added. neet Laboratoriot (Helsinki) were used [6] .
Travel. The cost of personal car use was calculated on the
